Abstract
Mutations in the K-ras oncogene and mutations or deletions in the tumor suppressor gene p53 are the two most prevalent oncogenetic alterations in human lung cancer. Ras mutations occur primarily in lung adenocarcinomas and small numbers of large cell undifferentiated and squamous cell lung carcinomas, but have not been detected in small cell lung carcinomas. Approximately 30% of lung adenocarcinomas carry a ras mutation. In US and European studies, nearly all mutations occur in the K-ras gene, although N-ras and H-ras mutations have been detected occasionally (1). K-ras mutations occur predominantly in codon 12 with a G→T transversion (Table 1).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Rodenhuis, S. (1996) RAS oncogenes and human lung cancer, in Lung Cancer Principles and Practice (Pass, H I, Mitchell, J B, Johnson, D H., and Turrisi, A T., eds.), Lippincott-Raven, Philadelphia, pp. 73–82
McCormick, F (1993) Signal transduction How receptors turn ras in Nature 363, 15,16
Sun, J, Qian, Y., Hamilton A. D, and Sebti, S M (1995) Ras CAAX peptidomimetic FTI276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-ras mutation and p53 deletion. Cancer Res 55, 4243–4247.
Lowy, D. R and Willumsen, B. M (1995) Rational cancer therapy Nature Med 1, 747,748
Chang, E H, Miller, P. S., Cushman, C., Devadas, K, Pirollo, K F., Ts’o, P 0, and Yu, Z. P. (1991) Antisense inhibition of ras p21 expression that is sensitive to a point mutation. Biochemistry 30, 8283–8286.
Tidd, D. M. (1990) A potential role for antisense oligonucleotide analogues in the development of oncogene targeted cancer chemotherapy. Ani-Cancer Res 10, 1169–1182
Zhang, Y., Mukhopadhyay, T., Donehower, L. A., Georges, R. N., and Roth, J. A. (1993) Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Human Gene Therapy 4, 451–460
Georges, R N, Mukhopadhyay, T., Zhang, Y., Yen, N, and Roth, J. A (1993) Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res 53, 1743–1746.
Cech, T R. (1990) Self-splicing of Group I intions. Annu Rev Biochem 59, 543–568
Kijima, H., Ishida, H., Ohkawa, T., Kashani-Sabet, M, and Scanlon, K. J. (1995) Therapeutic applications of ribozymes. Pharmacol Therap 68, 247–267
Cech, T. R. and Uhlenbeck, O. C (1994) Hammerhead nailed down. Nature 372, 39,40.
Koizumi, M., Kamiya, H., and Ohtsuka, E. (1992) Ribozyme designed to inhibit transformation of NIH3T3 cells by the activated c-Ha-ras gene. Gene 117, 179–184.
Bennett, M. J and Cullimore, J. V. (1992) Selective cleavage of closely related mRNAs by synthetic ribozymes. Nucleic Acids Res 20, 831–837
Haseloff, J. and Gerlach, W L. (1988) Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 334, 585–591
Ruffner, D. E, Stormo, G. D., and Uhlenbeck, O. C. (1990) Sequence requirements of the hammerhead RNA self-cleavage reaction. Biochemistry 29, 10,695–10,702.
Funato, T, Shitara, T., Tone, T., Jiao, Lu, Kashani-Sabet, M., and Scanlon, K. J. (1994) Suppression of H-ras-mediated transformation in NIH3T3 cells by a ras ribozyme. Blochem Pharmacol 48, 1471–1475.
Feng, M, Cabrera G, Desane, J, Scanlon, K. J, and Curiel, D. T. (1995) Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res 55, 2024–2028.
Kashani-Sabet, M. and Scanlon, K J (1995) Application of ribozymes to cancer gene therapy. Cancer Gene Therapy 2, 213–223.
Strauss, G. M., Kwiatkowski, D. J., Harpole, D. H., Lynch, T. J, Skarin, A T, and Sugarbaker, D J. (1995) Molecular and pathologic markers in stage I non-smallcell carcinoma of the lung J Clin. Oncol 13, 1265–1279.
Zhang, Y., Nemunaitis, J., Mues, G, Scanlon, K J., and Tong, A. W. (1996) In vitro suppression of human non-small cell lung cancer (NSCLC) cell growth by an anti-K-ras ribozyme (abstract). FASEB J 10, A1409.
Nemunaitis, J, Klemow, S., Tong, A., Courtney, A., Johnston, W., Mack, M., Taylor, W., Solano, M., Stone, M., Mallams, J., and Mues, G. (1997) Prognostic value of ras mutations, K-ras oncoprotein and c-erb B-2 oncoprotein expression in adenocarcinoma of the lung Ann J Clin. Oncol. (in press).
Ohta Y., Kijima, H., Kashani-Sabet, M., and Scanlon, K J (1996) Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes J Invest Dermatol 106, 275–280
kijima, H., Bouffard, D Y., and Scanlon, K J. (1996) Ribozyme-mediated reversal of human pancreatic carcinoma phenotype, in Proceedings of International Symposium on Bone Marrow Transplantation (Ikehara, S, ed.), Verlag-Springer, Tokyo, pp. 153–163
Snyder, D S., Wu, Y, Wang, J L, Rossi, J. J, Swiderski, P, Kaplan, B E, Forman, S. J (1993) Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line Blood 82, 600–605
Gunning, P, Leavitt, J, Muscat, G, Ng, S Y, Kedes, L (1987) A human β-actin expression vector system directs high-level accumulation of antisense transcripts. Proc Natl Acad Sci USA 84, 4831–4835
Larrson, S., Hotchkiss, G., Andang, M., Nyholm, T, Inzunza, J, Jansoon, I, and Ahrlund-Richter, L. (1994) Reduced β2-microglobulin mRNA levels in transgenic mice expressing a designed hammerhead ribozyme Nucleic Acids Res 22, 2242–2248
Sambrook, J, Fritsch, E. F, and Maniatis, T. (1989) DNA Sequencing in Molecular Cloning A Laboratory Manual, 2nd ed (Ford, N, Nolan, C, and Ferguson, M, eds), Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp 13.42–13 77
Becker, T C, Noel, R J., Coats, W. S., Gomez-Foix, A. M, Alam, T, Gerard, R. D, and Newgard, C B. (1994) Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Bzol 43, 161–189
Graham, F L and Prevec, L (1991) Manipulation of adenovirus vectors in Methods in molecular Biology, vol 7 Gene Transfer and Expression Protocols (Murray, E J., ed), Humana, Clifton, NJ, pp 109–128
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Humana Press Inc.
About this protocol
Cite this protocol
Tong, A.W., Zhang, YA., Nemunaitis, J., Mues, G. (1998). K-rasRibozyme for Lung Cancer. In: Scanlon, K.J. (eds) Therapeutic Applications of Ribozymes. Methods in Molecular Medicine™, vol 11. Springer, Totowa, NJ. https://doi.org/10.1385/0-89603-477-1:209
Download citation
DOI: https://doi.org/10.1385/0-89603-477-1:209
Publisher Name: Springer, Totowa, NJ
Print ISBN: 978-0-89603-477-8
Online ISBN: 978-1-59259-595-2
eBook Packages: Springer Protocols